Differences in breast cancer survival by molecular subtypes in the United States

Cancer Epidemiology Biomarkers and Prevention

Volumn 27, Issue 6, 2018, Pages 619-626

  Howlader, Nadia ^a   Cronin, Kathleen A ^a   Kurian, Allison W ^b   Andridge, Rebecca ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLACK PERSON; BREAST CANCER MOLECULAR SUBTYPE; BREAST SURGERY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER; TUMOR INVASION; TUMOR VOLUME; UNITED STATES; BREAST TUMOR; METABOLISM; MIDDLE AGED; MORTALITY;

AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; SURVIVAL RATE;

EID: 85047957147     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-17-0627     Document Type: Article

References (33)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747–52.
2. Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Nat Cancer Inst 2015;107:djv048–djv.
3. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 Status. J Nat Cancer Inst 2014;106:dju055–dju.
4. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 2012;104:1094–101.
5. Howlader N, Chen VW, Ries LA, Loch MM, Lee R, DeSantis C, et al. Overview of breast cancer collaborative stage data items–their definitions, quality, usage, and clinical implications: a review of SEER data for 2004-2010. Cancer 2014;120:3771–80.
6. Anderson WF, Rosenberg PS, Katki HA. Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer. J Nat Cancer Inst 2014;106:dju093–dju.
7. Keegan TH, Derouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res 2012;14:R55.
8. Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724–34.
9. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733–43.
10. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastu-zumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783–91.
11. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomark Prev 2012;21:1848–55.
12. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009;7:4–13.
13. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295: 2492–502.
14. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007;109:1721–8.
15. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J 2009;15: 593–602.
16. Bauer K, Parise C, Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer 2010;10:228.
17. Tao L, Gomez SL, Keegan THM, Kurian AW, Clarke CA. Breast cancer mortality in African-American and non-Hispanic white women by molecular subtype and stage at diagnosis: a population-based study. Cancer Epidemiol Biomark Prev 2015;24:1039–45.
18. Tao L, Chu L, Wang LI, Moy L, Brammer M, Song C, et al. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population. Cancer Causes Control 2016;27:1127–38.
19. O'Brien KM, Cole SR, Tse C-K, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010;16:6100–10.
20. Howlader N, Ries LAG, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Nat Cancer Inst 2010;102:1584–98.
21. Howlader N, Noone AM, Yu M, Cronin KA. Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer. Am J Epidemiol 2012;176:347–56.
22. Andridge R, Noone A-M, Howlader N. Imputing estrogen receptor (ER) status in a population-based cancer registry: a sensitivity analysis. Stat Med 2017;36:1014–28.
23. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2011;30:377–99.
24. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med 2009;28:1982–98.
25. Little RJA RD. Statistical analysis with missing data. New York, NY: John Wiley & Sons, Inc; 2002.
26. Anderson WF, Chen BE, Jatoi I, Rosenberg PS. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat 2006;100:121–6.
27. Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, et al. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 2017;161:279–87.
28. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009;113:357–70.
29. Surveillance Research Program DoCCaPS, National Cancer Institute. SEERStat Software. Bethesda, MD: National Cancer Institute; 2010.
30. Johnson CJ WH, Yin D, Niu X. The impact of patient follow-up on population-based survival rates. J Registry Manag 2010;37.
31. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA 2004;291:2720–6.
32. Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, et al. Patient income level and cancer clinical trial participation. J Clin Oncol 2013;31:536–42.
33. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017;389:1195–205.